Opendata, web and dolomites

MARSI SIGNED

Disruptive technologies for effectively rehabilitating chronic ambulatory disability

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MARSI project word cloud

Explore the words cloud of the MARSI project. It provides you a very rough idea of what is the project "MARSI" about.

joints    health    quadriplegia    medicines    cord    speed    neurological    daily    life    strength    palsy    minimize    15    weakness    functional    expectancy    worlwide    complications    programs    mobility    renting    81    injury    disabled    million    physically    autonomy    min    muscles    walking    treatments    market    quality    cerebral    remaining    losing    neuromuscular    disorders    synchronized    device    covers    motor    muscle    walk    progressive    nervous    overcome    alliance    diseases    bifida    models    lower    marsi    2023    paraplegia    portfolio    ambulatory    disorder    difficulty    impedes    everyday    sum    company    people    physical    critical    roughly    psychosocial    bionics    effortlessly    sme    share    minimal    acquiring    joining    powered    jobs    active    correspond    certification    spinal    orthoses    week    expensive    patients    avoiding    industrialization    showing    restore    commercialized    lifestyle    ares    escribano    limited    dementia    disability    spina    elders    sessions    house    turnover    14    time    barrier    function    enlarge    safely    frame    musculoskeletal    industrial    stroke    therapeutic    36m    rehabilitation   

Project "MARSI" data sheet

The following table provides information about the project.

Coordinator
MARSI BIONICS SL 

Organization address
address: CALLE RUE DEL PERCEBE 30
city: RIVAS VACIAMADRID
postcode: 28521
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.marsibionics.com/
 Total cost 2˙499˙150 €
 EC max contribution 1˙640˙730 € (66%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MARSI BIONICS SL ES (RIVAS VACIAMADRID) coordinator 1˙640˙730.00

Map

 Project objective

Worlwide, about 60 million people have some kind of difficulty in walking, which is related to some neurological disorder (stroke, dementia, neuromuscular diseases, etc). Roughly 40 million of affected correspond to elders and the % is higher in Europe. The remaining is the sum of physically disabled by cerebral palsy (14 million), neuromuscular diseases (4 million), spinal cord injury (paraplegia and quadriplegia, 3 million) and spina bifida (3 million). Neurological disorders affect the lower motor of the nervous system and share the progressive muscle weakness, which lead to several walk disability, loss of autonomy and psychosocial consequences. Most therapeutic treatments are limited to medicines and musculoskeletal rehabilitation programs, which are very expensive and limited to 15-30 min/week rehabilitation sessions. Active lifestyle is the most effective measure to restore the physical conditions. But the loss of muscle strength impedes the ambulatory function. The need is for a device allowing them walking effortlessly and safely in the everyday life activities. Based on our ARES technology, -the minimal functional unit providing synchronized joints-muscles mobility- Marsi Bionics has developed powered orthoses for in-house rehabilitation of patients affected by muscle weakness disorders, showing a product portfolio that covers the needs of a wide range of Neurological Disorders. Marsi products will be commercialized under renting models allowing patients acquiring it for daily use. This technology will improve these patients life quality and enlarge life expectancy by avoiding critical health complications of losing walking ability. Marsi is strengthened by joining with a leading company in the current industrial market, ESCRIBANO. This alliance in the frame of SME Phase 2 will speed up industrialization, overcome the certification barrier and minimize the time to market. As a result, we expect to reach above 36M€ turnover in 2023 and 81 generated jobs.

 Deliverables

List of deliverables.
Dissemination and Communication continuous monitoring (actions, results, congresses, materials and KPI. Documents, reports 2020-03-04 09:47:52

Take a look to the deliverables list in detail:  detailed list of MARSI deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MARSI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MARSI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

JUMPAIR (2018)

Decubitus Ulcers Diseases Diagnoses by means of Smart ICT Anti-Decubitus System based on known Ulcers Activity Biomarkers

Read More  

PRIDIKTIV (2017)

Pridiktiv - Exploring European expansion through 4 pilot studies

Read More